MARKET

REGN

REGN

Regeneron Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

567.04
-15.48
-2.66%
After Hours: 578.14 +11.1 +1.96% 19:58 10/28 EDT
OPEN
576.69
PREV CLOSE
582.52
HIGH
578.98
LOW
563.87
VOLUME
592.95K
TURNOVER
--
52 WEEK HIGH
664.64
52 WEEK LOW
303.22
MARKET CAP
60.33B
P/E (TTM)
21.95
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Regeneron Says COVID-19 Antibody Cocktail Reduced Viral Load, Need For Medical Care In Late-Stage Trial
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) said Wednesday data from late-stage clinical trials is indicative that its antibody cocktail for COVID-19 both reduced viral load and need for medical attention.
Benzinga · 3h ago
Regeneron says its Covid-19 antibody treatment cut medical visits in trial
Regeneron Pharmaceuticals said on Wednesday its coronavirus antibody cocktail significantly reduced medical visits in a trial of nearly 800 patients.
Reuters · 6h ago
Regeneron: Trial COVID-19 drug cocktail cut virus load in more people
Shares of Regeneron Pharmaceuticals Inc. undefined rose more than 3% in the extended session Wednesday after the company said its experimental antibody...
MarketWatch · 6h ago
Regeneron's COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention
Today's data, involving an additional 524 patients from the ongoing Phase 2/3 trial, provides definitive final virology results and meets the clinical endpoint of reducing medical visits
PR Newswire · 7h ago
Regeneron +2.5% as prospective COVID-19 trial results show reduced medical visits
Regeneron (REGN) is up 2.5% after hours after it announced prospective results from its ongoing Phase 2/3 seamless trial of its COVID-19 antibody drug. The trial prospectively shows that the
Seekingalpha · 7h ago
Regeneron’s Covid-19 Therapy Reduces Viral Load, Need for Care
Regeneron Pharmaceuticals Inc. said data from a late-stage clinical trial suggest that its antibody cocktail therapy for Covid-19 significantly reduces virus levels and the need for further medical care.
Bloomberg · 7h ago
Regeneron Reports COVID-19 Outpatient Trial Prospectively Shows Co.'s COVID-19 Antibody Cocktail Significantly Reduced Virus Levels, Need For Further Medical Attention
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail,
Benzinga · 8h ago
U.S. to Buy Lilly Antibody; Germany’s New Curbs: Virus Update
The U.S. agreed to pay Eli Lilly & Co. $375 million for 300,000 vials of its experimental Covid-19 antibody, underscoring governments’ appetite for any pandemic solution as the virus stages a comeback in the northern hemisphere.
Bloomberg · 17h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of REGN. Analyze the recent business situations of Regeneron Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 27 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average REGN stock price target is 679.17 with a high estimate of 800.00 and a low estimate of 550.00.
EPS
Institutional Holdings
Institutions: 1.19K
Institutional Holdings: 95.59M
% Owned: 89.85%
Shares Outstanding: 106.39M
TypeInstitutionsShares
Increased
375
19.09M
New
265
859.79K
Decreased
234
3.31M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-2.11%
Key Executives
Chairman/Director
P. Roy Vagelos
President/Chief Executive Officer/Director
Leonard Schleifer
Co-President/Chief Scientific Officer/Director
George Yancopoulos
Chief Financial Officer/Executive Vice President - Finance
Robert Landry
Executive Vice President/General Counsel/Secretary
Joseph LaRosa
Executive Vice President/General Manager
Daniel Van Plew
Executive Vice President
Andrew Murphy
Executive Vice President
Neil Stahl
Senior Vice President
Marion McCourt
Vice President/Controller
Christopher Fenimore
Independent Director
Bonnie Bassler
Independent Director
Michael Brown
Independent Director
N. Anthony Coles
Independent Director
Joseph Goldstein
Independent Director
Christine Poon
Independent Director
Arthur Ryan
Independent Director
George Sing
Independent Director
Marc Tessier-Lavigne
Independent Director
Huda Zoghbi
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About REGN
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Regeneron Pharmaceuticals Inc stock information, including NASDAQ:REGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading REGN stock methods without spending real money on the virtual paper trading platform.